Summary:
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
- MACD is crossing MACD signal line at 0.3. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
Abbott Laboratories' rapid COVID-19 antigen test is highly likely to correctly detect if people have ever contracted the virus and could help with earlier isolation, according to the U.S. Centers for Disease Control and Prevention. The test was less sensitive in detecting asymptomatic infection, but the CDC study found that the faster turnaround time can help limit transmission by more rapidly identifying infectious persons for isolation. Several rapid antigen tests have been approved by the U...
Nearby levels of support and recent closes beyond key resistance are creating lucrative risk/reward setups in the healthcare sector.
The equipment, made by companies such as Medtronic and Abbott Laboratories, offers an alternative to drugs for pain relief.
With multiple COVID-19 vaccines being distributed across the world, companies focused on other medical conditions are now grabbing the Street's attention. One such disorder is diabetes, which is growing rapidly worldwide—sedentary lifestyles being a key reason for that. A recent report by the World Health Organization (WHO) revealed that deaths from diabetes surged 70% globally between 2019 and 2020. Abbott and Dexcom are some of the names that are developing diabetes monitoring systems. Using t...
Real Money contributor Stephen Guilfoyle checks which sector names could perform best over the coming year.
The Zacks Analyst Blog Highlights: Abbott Lab, QIAGEN, Quidel, Hologic and Quest Diagnostics
Abbott (NYSE: ABT) today announced the upcoming launch of NeuroSphere™ myPath™, a digital health app designed to track and report on patient perceived pain relief and general well-being associated with spinal cord stimulation (SCS) or dorsal root ganglion (DRG) therapy. During the device trial period required before the permanent implant, the app allows patients to record their outcomes on pain and well-being while trialing their neurostimulation therapy.
Yahoo Finance's Anjalee Khemlani sat down with LabCorp CEO Adam Schechter to discuss the latest with the company, it's transition to coronavirus testing, and what to expect from their latest products.
The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.